Browse by author
Lookup NU author(s): Professor Andrew FisherORCiD, Dr Robert Rutherford, Dr Joseph Bozzino, Professor John Dark
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Total lymphoid irradiation (TLI) has been used to control renal and cardiac allograft rejection. Data evaluating TLI in bronchiolitis obliterans syndrome (BOS), the physiological manifestation of chronic lung allograft rejection, is very limited. We present our single center experience of the safety and efficacy of TLI in controlling progressive BOS in a retrospective study. Over 12 years, 37 lung recipients (16 M:21 F) who had undergone 13 single; 12 bilateral and 12 heart-lung transplants were treated with TLI for progressive BOS. Grades at time TLI given were BOS 1 (n = 7) BOS 2 (n = 14) BOSS (n = 16). Twenty-seven (73%) completed >8/10 fractions, 10 (27%) failed to complete TLI. Two died from advanced BOS during treatment, 8 stopped early (range 3-7 fractions) due to marrow suppression (6) or infection (2). In the 27 recipients who completed >8/10 fractions, decline in FEV1 was 122.7 mis/month pre-TLI and 25.1 mis/month post-TLI, p = 0.0004, mean (95% CI) change in rate of decline was 97.5 (48.2-146.7) mis/month. TLI significantly reduces the rate of decline in graft function associated with BOS. TLI is well tolerated and associated with few serious complications and is an appropriate immunosuppressive approach in progressive BOS. Copyright © Blackwell Munksgaard 2004.
Author(s): Fisher AJ, Rutherford RM, Bozzino J, Parry G, Dark JH, Corris PA
Publication type: Article
Publication status: Published
Journal: American Journal of Transplantation
Year: 2005
Volume: 5
Issue: 3
Pages: 537-543
Print publication date: 01/03/2005
ISSN (print): 1600-6135
ISSN (electronic): 1600-6143
Publisher: Wiley-Blackwell
URL: http://dx.doi.org/10.1111/j.1600-6143.2004.00709.x
DOI: 10.1111/j.1600-6143.2004.00709.x
PubMed id: 15707408
Altmetrics provided by Altmetric
